NCT02502253View on ClinicalTrials.gov

BDPP Treatment for Mild Cognitive Impairment (MCI) and Prediabetes or Type 2 Diabetes Mellitus (T2DM)

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

June 1, 2022

Study Completion Date

June 1, 2022

Conditions
Mild Cognitive ImpairmentAlzheimer's Disease
Interventions
DRUG

grape seed polyphenolic extract, resveratrol

Bioactive Dietary Polyphenol Preparation (BDPP) is a combination of two nutraceutical preparations (grape seed polyphenolic extract \[GSE\], and resveratrol) that contain abundant concentrations of polyphenols.

Trial Locations (1)

21224

Johns Hopkins University, Baltimore

All Listed Sponsors
collaborator

Icahn School of Medicine at Mount Sinai

OTHER

lead

Johns Hopkins University

OTHER

NCT02502253 - BDPP Treatment for Mild Cognitive Impairment (MCI) and Prediabetes or Type 2 Diabetes Mellitus (T2DM) | Biotech Hunter | Biotech Hunter